FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Can cancer cells communicate? February 28, 2023 Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes June 3, 2022 FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease August 18, 2021 Middle Schooler Starts Business to Help Provide Spa and Salon Services... April 5, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with... How Do Black People with Cancer View Clinical Research?
